GLP-3 RT – 50mg

GLP-3 RT (the widely utilized research designation for the investigational triple-agonist peptide retatrutide, developmental code LY3437943) is a groundbreaking, 39-amino-acid acylated peptide. Structurally modified to concurrently activate three distinct metabolic hormone pathways, it functions as a triple GLP-1, GIP, and glucagon receptor agonist. The inclusion of the third target (glucagon) differentiates it from earlier single-receptor and dual-receptor molecules. Conjugated to a C18 fatty diacid sidechain to facilitate high-affinity, reversible albumin binding, GLP-3 RT displays robust structural stability, an extended biological half-life of approximately 6 days, and complete resistance to DPP-4 enzymatic degradation. [1, 2]

Key Features & Characteristics

• Mechanism of Action: Simultaneously stimulates three core pathways: the Glucagon-Like Peptide-1 (GLP-1) receptor, the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor, and the Glucagon receptor. [1]
• Engineered Balance: Exhibits imbalanced, biased signaling—functioning as a potent agonist at the GIP receptor while operating with calibrated partial-agonist properties at the GLP-1 and glucagon sites. [1]
• Extended Pharmacokinetics: Fatty acid acylation minimizes renal clearance, allowing a prolonged baseline duration (~6 days) to sustain constant receptor engagement in animal models. [1, 2]
• Physical Form: Synthesized to maximum chemical thresholds and supplied as a stable, sterile-filtered lyophilized white powder engineered for stable, long-term laboratory storage. [1]

Primary Research Applications

• Triple-Incretin Signaling & Energy Balance: Heavily studied in obesity and morbid obesity models to chart how the combination of appetite-suppressing GLP-1/GIP signaling works with the energy-expenditure and metabolic-rate-boosting properties of glucagon.
• Hepatic Lipid Metabolism & Steatosis: Investigated in preclinical models of non-alcoholic fatty liver disease (NAFLD) to evaluate its performance in driving rapid, accelerated fat oxidation directly inside hepatic structures.
• Glycemic Control & Insulin Feedback: Used in advanced type 2 diabetes research to monitor improvements in pancreatic beta-cell insulin response, blood glucose handling, and insulin resistance biomarkers. [1, 2, 3, 4, 5]

For Research Use Only. Not for human consumption, therapeutic, or diagnostic use.